Deloitte buys data warehouse firm

| | Health Exec | Economics

Deloitte Consulting Services has acquired Recombinant Data, a developer of data warehousing and clinical intelligence systems for personalized medicine, translational research and healthcare performance management. Terms of the acquisition were not disclosed.

Based in Newton, Mass., Recombinant, founded in 2005, seeks to relate to enterprise data integration, population health analytics, clinical genome data assimilation and performance management for accountable care organizations. According to Deloitte, Recombinant also seeks to assist academic medical centers, federal agencies and life sciences companies conduct translational research and analyze phenomic, genomic and bio-banking data in pursing personalized and evidence-based medicine.

Recombinant’s business will reside within Deloitte Consulting Innovation under the name “Recombinant By Deloitte.”

 

 

Related Content

Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations
Cleerly’s momentum continues as AI specialists raise $106M
Operations manager, doctors charged in $70M imaging kickback scheme
Private-equity watchdog warns against nominating Marc Rowan as Treasury Secretary

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.